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Complete protection from gentamicin-induced acute renal failure in the
diabetic rat. The possible protective effect of solute and water diuresis
on the development of acute renal failure (ARF) following administra-
tion of gentamicin, 40 mg/kg of body wt per day for 14 days, was studied
in unanesthetized rats. Adult female Sprague-Dawley rats with strepto-
zotocin-induced diabetes mellitus (DM) and rats with hereditary diabe-
tes insipidus (DI) were used as models of chronic solute and water
diuresis, respectively. Aged-matched Sprague-Dawley (C) and hetero-
zygous Brattleboro (BC) rats were the respective controls. Because of
higher creatinine clearance (C) in the DM rats, another DM group
received a higher dose of gentamicin (DM-H), 70mg/kg/day for 14 days.
C and DM animals injected with Ringer's were SHAM-C and SHAM-
DM groups. Following gentamicin, C rats developed ARF (maximal
decrease in Ccr from baseline was 85 6(sEM)%; P < 0.001), severe
lysozymuria, and tubular necrosis. In marked contrast, all DM and DM-
H rats exhibited complete functional and morphologic integrity with
undetectable lysozymuria; no differences were observed between the
two diabetic groups. BC and DI rats exhibited a 56 7% (P < 0.001)
and 38 8% (P < 0.01) maximal decrease in Ccr, lysozymuria, and
tubular necrosis. SHAM-C and DM rats maintained unchanged renal
function throughout. The kidney content of gentamicin analyzed on day
15 of the study was significantly lower in the DM and DM-H rats than in
C, while no differences were found between BC and DI rats. In a
separate group of Sprague-Dawley C and DM rats, renal cortical
gentamicin content was measured 3, 6, and 9 days after beginning
gentamicin administration at 40 mg/kg/day. By day 3 the DM rats had a
cortical gentamicin content that was three-fold lower (164 18 gIg wet
tissue) than that of C animals (523 55; P < 0.005). The latter group
subsequently developed acute renal failure and lysozymuria. We con-
clude that in contrast to the development of gentamicin-induced ARF in
C and BC rats, complete protection was afforded in the DM and DM-H
animals. Partial protection was observed in the DI group. Protection in
the DM animals was associated with lower renal cortical gentamicin
content, suggesting that factors influencing the early cellular uptake of
gentamicin may have determined the protection exhibited by these
animals. The mechanism(s) whereby this occurred remain(s) to be
elucidated but cannot be ascribed solely to enhanced solute excretion in
the diabetic rats. The rat with streptozotocin-induced diabetes mellitus
is a useful model for the study of gentamicin-induced nephrotoxicity.
Protection complete contre l'insuffisance rénale aigue induite par Ia
gentamicine chez le rat ayant un diabète sucré. Un effet possible d'une
diurèse d'eau et de solutés sur le developpement de l'insuffisance rénale
aigue (IRA) par administration de gentamicine, 40 mg/kg/j pendant 14jours était étudié, chez des rats non anesthésiés. Des rats femelles
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adultes Sprague-Dawley ayant un diabCte sucrC (DS) induit par Ia
streptozotocine, et des rats ayant un diabCte insipide (DI) héréditaire
ont été utilisés comme modéle de diurése chronique de solutés et de
diurèse aqueuse respectivement. Des rats Sprague-Dawley (C) du
mCme age, et des rats Brattleboro (BC) heterozygotes ont servi respec-
tivement de contrôle. En raison de Ia plus grande déblaiement de
creatinine (Ccr) des rats DS, un autre groupe de rats DS a recu une plus
forte dose de gentamicine (DS-H), 70 mg/kg/j/l4jours. Des animaux C et
DS recevant du Ringer ont servi de groupes contrôles. Aprés Ia
gentamicine, chez les rats C, sont apparues une IRA (abaissement
maximum de Ce,. de 85 6% SEM a partir de Ia valeur de base, P <
0,001), une lysozymurie sévCre, et une nCcrose tubulaire. Au contraire,
tous les rats DS et DS-H ont conserve une intégrité fonctionnelle et
morphologique totale avec une lysozymurie indCtectable, sans differ-
ence entre ces deux groupes de rats diabetiques. Chez les rats BC et DI,
sont apparues une diminution de Cr (56 7%, P < 0,001, Ct 38 8%,
P < 0.01), une lysozymurie et une nécrose tubulaire. Les rats contrôles
C et DS ont conserve une fonction rCnale inchangee. Le contenu renal
de gentamicine, mesuré 15 jours aprCs l'Ctude était significativement
plus bas chez les rats DS et DS-H que chez les C, et il n'y avait pas de
difference entre les rats BC et DI. Dans d'autres groupes de rats
Sprague-Dawley C et DS, le contenu de gentamicine dans Ia corticale
rCnale a Cté mesurC 3, 6 et 9jours aprCs de debut de l'administration de
gentamicine ala dose de 40 mg/kg/j. Des le 3 jour, les rats DS avaient un
contenu cortical en gentamicine trois fois moindre (164 18 pg/g de
tissu humide) que celui des animaux C (523 55, P < 0.005). Chez le
dernier groupe sont apparues une insuffisance rénale aiguC et une
lysozymurie. Nous concluons que par opposition au dCveloppement
d'une IRA aprés gentamicine chez les rats C et BC, une protection
totale s'est manifestCe chez les animaux DS et DS-H. Une protection
partielle a etC observCe dans le groupe DI. La protection des animaux
DS allait de pair avec un plus faible contenu en gentamicine dans Ia
corticale rCnale, ce qui suggCre que les facteurs influencant l'entrCe
prCcoce de Ia gentamicine dans Ia cellule pourraient avoir dCterminC Ia
protection observCe chez ces animaux. Le(s) mCcanisme(s) de cette
protection reste(nt) a prCciser, mais il(s) ne se rCsume(nt) pas seulement
a une augmentation accrue des solutCs chez les rats diabCtiques. Le rat
ayant un diabCte sucrC induit par Ia streptozotocine est un modCle utile
pour l'Ctude de Ia nCphrotoxicitC due a Ia gentamicine,
The administration of aminoglycosides is often associated
with the development of acute renal failure. In the rat, gentami-
cm has been extensively studied as a prototype of this group of
drugs and as a model of nephrotoxic acute renal failure (ARF)
[1].
Maneuvers to prevent or attenuate the development of ARF
have been tried for many years in various experimental models
[2—101. Attempts to protect animals from the development of
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gentamicin-induced ARF with hydration [11], high sodium
intake [12], diuretics [13—15], urinary alkalinization [16, 17] and
amino acids administration [18], have resulted in little or no
protection. Preservation of renal function with presence of
proximal tubular damage has been recently demonstrated in the
gentamicin-treated rat with concomitant administration of sa-
line and captopril or with captopril alone [19].
The aim of this study was to evaluate the possible protective
effect of solute and water diuresis on the development of ARF
secondary to the administration of gentamicin following a
standard regimen of 40 mg/kg of body wt per day for 14 days.
The rat with untreated streptozotocin-induced diabetes mellitus
was used as a model of chronic solute diuresis and the rat with
hereditary diabetes insipidus as a model of chronic water
diuresis.
The animals with diabetes mellitus showed complete protec-
tion from gentamicin-induced-ARF, as evidenced by an ab-
sence of lysozymuria, an impairment of creatinine clearance,
and a morphologic evidence of tubular necrosis. In marked
contrast, the control rats developed ARF with severe lysozy-
muria and tubular necrosis. Partial protection was observed in
the rats with hereditary diabetes insipidus. The observed pro-
tection in the animals with diabetes mellitus was associated
with a lower renal cortical gentamicin content. Factor(s) re-
sponsible for the early lower gentamicin renal accumulation
appeared responsible for the protection afforded against genta-
micin-induced ARF by the diabetic rats.
Methods
Adult female rats of Sprague-Dawley (Charles River Breed-
ing Laboratory, Wilmington, Massachusetts, CD strain) and
Brattleboro strains were used. The Sprague-Dawley rats were
divided into two age-matched groups: control (C) and untreated
diabetes mellitus (DM). Diabetes mellitus was induced by an
intravenous administration of streptozotocin, 65 mg/kg of body
wt (BW), given 4 to 6 months before the studies as described by
Junod et al [20]. The diabetic state was defined as persistent
nonfasting elevated plasma glucose levels (>500 mg/dl), persist-
ent + + + to + + + + glycosuria and marked polyuria (daily
urine volume >75 ml).
The Brattleboro rats were also divided into two age-matched
groups: The heterozygous animals were designated as Brattle-
boro controls (BC) and the homozygous rats as diabetes insipi-
dus (DI). The latter characteristically showed marked polyuria
and lower urine osmolality. Twenty-four hr urine volumes in
these animals ranged from 65 to 120% of their body weights. All
animals were housed in individual metabolic cages for 3 weeks,
allowed free access to water, and fed a standard rat chow diet
ad libitum. Special care was exercised to provide sufficient
water and food to the diuretic animals. Pair-feeding was not
used in our study because of the hypercatabolism and high food
consumption of rats with experimental diabetes mellitus, and
the risk of development of ketosis and dehydration by food
intake reduction. The cages were equipped with screens to
avoid fecal contamination and were also designed to exclude
urine contamination with food or drinking water. The urine was
collected directly into siliconized aluminum pans covered with
mineral oil. After an adaptation period of 3 days, a baseline
period of 1 to 4 days was obtained. Because there was little
variation in the results obtained during these baseline days, all
data were averaged and will be referred to as baseline values.
During the experimental period of 14 days, all four groups of
rats were given 40 mg/kg BW per day of gentamicin sulfate
(Schering Corporation, Bloomfield, New Jersey), subcutane-
ously in equally divided doses at 9 A.M. and 5 P.M.
Because the rats with experimentally-induced diabetes melli-
tus had a higher creatinine clearance (Ccr) and lower body
weight than control animals, which might influence the renal
handling of gentamicin, additional animals were studied. Six
untreated rats with diabetes mellitus received a higher dose of
gentamicin (70 mg/kg BW per day for 14 days in two subcutane-
ous injections) and were designated diabetes mellitus-high dose
(DM-H). In addition, five Sprague-Dawley control and five
diabetes mellitus rats were equally treated except that Ringer's
solution was injected twice a day instead of gentamicin. These
animals were designated as SHAM-controls and SHAM-DM,
respectively.
To examine the relationship of renal accumulation of genta-
micin to functional changes, additional studies were done in 36
female Sprague-Dawley control and diabetes mellitus rats.
These animals were prepared and studied as described previ-
ously. After obtaining baseline values all rats were injected
subcutaneously with 40 mg/kg BW/day of gentamicin for 9 days
given in two divided doses. Clearance studies were repeated on
days 3, 6, and 9 after commencing gentamicin and animals were
sacrificed immediately after in groups of six animals each.
Gentamicin was assessed in these groups in the renal cortex
rather than in the whole kidney.
Tail blood samples and 24-hr urine collections were obtained
during baseline and on days 4, 7, 11, and 14 of the experimental
period. Hematocnt, BUN and plasma glucose, creatinine,
sodium, potassium, and osmolality were determined. Urine
volume, osmolality, glucose, creatinine, sodium, potassium,
and lysozyme concentrations were measured in the 24-hr urine
collections. Body weights, water, and food intake were also
measured on the same days. Food was analyzed for sodium and
potassium content. Endogenous creatinine and osmolal clear-
ances were calculated by standard equations.
On day 15, under light mactin (Promonta, Hamburg, Germa-
ny) anesthesia, the abdominal aorta was surgically exposed and
retrogradely cannulated. It was clamped above the renal arter-
ies after perfusion with oxygenated Ringer's solution had been
started, and the inferior vena cava was opened. Immediately
after washing out the blood, as judged by blanching the paren-
chyma, the right renal pedicle was ligated and the kidney
removed for determination of tissue gentamicin content. Perfu-
sion fixation of the other kidney was begun with 100 ml of
Karnovsky's fixative at a pressure of 140 mm Hg and 37° C
temperature. The kidney was then removed and cut in slices
that were immersed in the same fixative used for perfusion for
at least 12 hr at 4° C. Slices were processed for light microscopy
and embedded in butoxyethanol-glycol-methacrylate (Polysci-
ences, Warrington, Pennsylvania), cut in a Sorvall JB-4 micro-
tome, and 2- to 3- thick sections stained with hematoxylin and
eosin and periodic acid-Schiff. For electron microscopy the
tissues were washed in 0.1 M phosphate buffer with sucrose and
cut in pieces of 1 mm3 dimensions. Postfixation was performed
in 1% osmium tetroxide in 0.1 phosphate buffer. After dehydra-
tion in graded series of alcohols and propylene oxide, the tissue
blocks were embedded in Epon. Semithin sections were stained
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Table 1. Baseline blood and renal function variables
Diabetes
Statistical differences between
groups, Unpaired t test, P values
DM
Diabetes mellitus high Brattleboro Diabetes C vs. C vs. vs. BC vs.
Controls (C) mellitus (DM) dose (DM4-f) controls (BC) insipidus (Dl) DM DM-H DM-H DI
N 9 10 6 9 9
Body weight g 305 12 220 13 219 13 294 7 206 7 <0.001 <0.001 NS <0.001
Hematocrit % 46 0.6 48 1.3 49 0.5 46 0.8 45 0.8 NS <0.025 NS NS
Plasma glucose
mg/dl 126 5 615 23 605 29 122 3 145 14 <0.001 <0.001 NS NS
Plasma creatinine
mg/di 0.46 0.01 0.29 0.01 0.25 0.01 0.46 0.01 0.39 0.02 <0.001 <0.001 NS <0.05
BUN mg/dl 16 1 26 2 26 3 20 1 18 2 <0.001 <0.005 NS NS
Plasma sodium
mEqiliter 146 1 141 1 143 3 149 1 154 1 <0.02 NS NS <0.005
Urine flow mi/day 11 1 109 9 142 12 23 1 192 17 <0.001 <0.001 <0.05 <0.001
Urine osmolality
mOsm/kg water 1316 108 960 23 897 24 956 56 124 7 <0.005 <0.01 NS <0.001
Cc,. mI/mm 1.6 0.2 2.3 0.2 2.2 0.2 1.6 0.1 1.3 0.1 <0.01 NS NS <0.025
Osmolal clearance
ijJ/min 25 4 228 2 237 2 51 3 48 5 <0.001 <0.001 NS NS
FENa % 0.2 0.04 0.6 0.07 0.6 0.09 0.5 0.02 0.5 0.04 <0.001 <0.001 NS NS
Urine glucose
glday 0.008 0.001 8.3 0.5 10.4 1 0.003 0.001 0.007 0.001 <0.001 <0.001 NS NS
Values are means SEM; N = number of animals in each group.
Abbreviations are FEjja, fractional excretion of sodium; Cc,., creatinine clearance; NS, nonsignificant, P > 0.05.
with toluidine blue and used to choose blocks oriented trans-
versely or longitudinally to the medullary rays. Ultrathin sec-
tions were stained with uranyl acetate and lead citrate.
The degree of tubular necrosis was evaluated by examining
coded light microscopy slides. Fifty kidneys from 53 animals
were available and tubular necrosis was graded according to a
scale (0 to 4). For each group the results were averaged and
expressed as a tubular necrosis score. Quantitative differences
between the various groups were analyzed by non-parametric
statistical methods (Mann-Whitney U test).
For the gentamicin assay in renal tissue a wedge of renal
cortex and medulla (animals sacrificed on day 15) or a segment
of the renal cortex (animals sacrificed immediately after days 3,
6, and 9) was removed, weighed, homogenized in 0.2 M tris-
buffer, and placed in a water bath at 56° C for 30 mm. The
homogenized tissue was removed from the bath and centrifuged
for 10 mm at 2000 rpm. The supernatant was then separated and
stored at 40 C for latter analysis. The kidney content of gentami-
cm was measured in duplicate by enzymatic radiochemical
assay ('4C gentamicin, P.L. Biochemicals, Inc., Milwaukee,
Wisconsin) and the results expressed as i.g/g of wet or dry
kidney tissue. Replication studies showed a 3.0 to 3.9% varia-
tion between samples. Gentamicin recoveries from renal tissue
were 91 1 (sEM)% (N = 20), with no differences observed
between C and DM rats. Weights were determined of kidneys
obtained for the gentamicin assay after removal of fat and gentle
blotting. The water content of renal tissue was determined by
drying to constant weight a representative renal segment in a
heater dessicator.
BUN, plasma glucose, and urinary creatinine (in the non-
glycosuric animals) were determined by standard techniques
adapted for automated analysis. Plasma and urine creatinine (in
the glycosuric rats) were determined by the method of Hare [211
using a Beckman spectrophotometer model 35. The effect of
high plasma and urine concentrations of glucose on creatinine
determinations was assessed because of the possibility of
interference at high glucose concentrations [221. No interfer-
ence in plasma was detected at the plasma glucose levels
encountered in this study (less than 1000 mgldl). Urine samples
with high urinary glucose concentrations (4 to 12 gIdl) showed a
slight tendency to give higher creatinine readings (less than
5%). The calculation of the endogenous creatinine clearance in
the unanesthestized undisturbed rat by combining the tech-
niques of Hare [21] for plasma and urine creatinine or Hare
for plasma creatinine and an automated technique for urinary
creatinine has provided excellent results (Vaamonde and Kel-
icy, unpublished observations). When compared with the simul-
taneously measured carbon 14 carboxyl inulin method the
following creatinine clearance/inulin clearance ratios were ob-
tained in our laboratory: creatinine clearance (plasma Hare,
urine Hare)/carbon 14 inulin clearance: 1.03 0.04 (N = 29);
creatinine clearance (plasma Hare, urine autoanalyzer)/carbon
14 inulin clearance 1.09 0.04 (N = 37).
Sodium and potassium concentrations were determined in an
IL flame photometer and osmolality in a Fiske osmometer.
Hematocrit was measured in triplicate with an International
Equipment Company microcapiliary centrifuge.
Lysozymuria was measured with a radial diffusion technique
(Hallstad Laboratories, Chaska, Minnesota) and the results
expressed in p.g/24 hr. Undetectable levels with this method
were less than 4.3 p.gIdl. Urine samples from polyuric rats (DM,
DI) were concentrated with lyphogel to confirm the absence of
lysozymuria. Urine glucose was determined with a Beckman
glucose analyzer utilizing the glucose oxidase method.
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Table 2. Balance data at baseline
Control (C)N=7 P
Diabetes
mellitusa (DM)
N=13
Brattleboro
control (BC)N=9 P
Diabetes
insipidus (Dl)N=9
Body Weight g 294 7 <0.001 205 8 294 7 <0.001 206 7
Water intake mi/day 24 2 <0.001 152 9 35 2 <0.001 203 14
Urine volume mi/day 11 1 <0.001 133 8 23 1 <0.001 192 17
Food intake g/day 12 1 <0.001 35 1 17 I NS 14 I
Sodium intake mEq/day 1.4 0.1 <0.001 3.9 0.2 1,8 0.1 NS 1.6 0.1
Sodium excretion mEq/day 1.0 0.1 <0.001 2.9 0.2 1.6 0.1 NS 1.7 0.1
Sodium balanceb mEqiday 0.4 0.03 <0.05 1.0 0.3 0.2 0.04 <0.005 0.1 0.08
Potassium intake mEq/day 3.0 0.2 <0.001 8.1 0.3 3.8 0.3 NS 3.3 0.1
Potassium excretion mEq/day 2.5 0.2 <0.001 6.5 0.3 3.2 0.3 NS 3.0 0.1
Potassium balanceb mEq/day 0.6 0.1 <0.001 1.6 0.2 0.6 0.1 <0.025 0.3 0.07
Includes both groups of DM rats, those treated with 40 and 70 mg/kg BW/day of gentamicin for 14 days (DM and DM-H). Except for urine vol-
ume (Table 1), there were no statistically significant differences between DM and DM-H rats in the variables included in this table.
b No measurement of fecal sodium and potassium was undertaken, thus, sodium and potassium balances reflect differences between intake and
urinary excretion. It should be noted, however, that the DM rats clearly had increased fecal losses of sodium and potassium due to their obvious
large stool formation (without diarrhea) secondary to a three-fold higher food intake.
P less than 0.05 or greater vs. baseline day
b P less than 0.05 or greater vs. SHAM controls, indicated only for creatinine clearance (Ce).
Values are presented as means SEM. Statistical analyses of
paired and unpaired data were performed according to standard
parametric and non-parametric techniques [23, 241.
Results
Baseline blood and renal function values (Tables I to 3)
Diabetes mellitus rats. There were no differences between
the DM and DM-H groups in any of the variables listed with the
exception of baseline urine volume, which was 30% greater in
the DM-H rats (Table 1).
Both DM groups weighed significantly less (P < 0.001) than
the Sprague-Dawley control animals. Baseline hematocrit val-
ues were not different with the exception of the DM-H group.
Marked hyperglycemia (P < 0.001), glycosuria (P <0.001) and
lower plasma creatinine (P < 0.001) levels were present in both
DM groups in comparison to controls. On the other hand, BUN
levels were higher in the diabetic rats. The discrepant baseline
BUN and plasma creatinine concentrations between Sprague-
Dawley control and DM rats has been consistently observed in
our laboratory in a larger number of animals studied under
similar controlled conditions'.
Although the mean plasma sodium concentration was within
the normal range in the Sprague-Dawley animals, it tended to be
lower in the DM groups. There was a tendency for the plasma
potassium levels to be slightly elevated in the hyperglycemic
animals: controls 5.1 1.4 mEq!liter; diabetes mellitus 5.8
0.7 mEq/liter; P < 0.05.
As expected, the urine flow rate was higher (P < 0.001) and
the urine osmolality lower (P < 0.01) in both DM groups. The
endogenous Ccr was higher in both DM groups than in controls,
'Average data from 32 Sprague-Dawley control and 42 streptozoto-
cm-induced diabetic rats: BUN, controls 9 1 mgldl; diabetes mellitus
14 I mg/dl, P < 0.001; plasma creatinine, controls 0.39 0.01 mg/dl,
diabetes mellitus 0.28 0.01 mg/dl, P < 0.001. The elevated BUN
concentrations in the DM rats probably result from the hypercatabolic
state of these animals.
Table 3. Blood and urinary values of SHAM control and diabetes mellitus Sprague-Dawley rats
Plasma Urine Urine
Body Wt Hematocrit glucose volume Urine glucose sodium
Study day g % mg/di mi/day g/day mEqlday Ccr mi/rn in
SHAM control rats (N = 5)
Baseline 280 5 43 1 114 3 16 2 0.004 0.001 0.9 0.1 2.1 0.1
4 276 7 43 1 110 4 17 2 0.003 0.001 1.1 0.1 1.7 0.1
7 275 7 42 Ia 107 4 18 3 0.004 0.001 1.1 0.la 1.6 1.0
11 271 8a 44 I Ill 3 19 3 0.004 0.001 1.3 0.la 2.0 0.1
14 265 9 44 1 113 2 16 1 0.004 0.001 1.2 0.1 1.9 0.1
SHAM Diabetes mellitus rats (N = 5)
Baseline 226 17 45 1 630 44 143 9 13.0 2.0 2.5 0.3 2.1 0.2
4 230 18 46 1 600 59 152 9 12.0 0.4 3.0 0.1 2.9 0.3a,b
7 232 16 47 l 587 21 147 6 12.8 1.1 2.9 0.2 2.8 0.lb
II 233 16 48 D 587 28 143 5 11.6 0.5 2.8 0.2 2.6 0.2
14 228 14 47 I 593 35 141 3 10.5 0.2 2.8 0.4 2.8 0.2
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Table 4. Creatinine clearance (C-), lysozymuria, and renal cortical
gentamicin content after administration of gentamicin (40 mg/kg/day
for 9 days) to control and diabetes mellitus (DM) rats
8
6
4
I
Day 3 Day6 Day9
C, % change from baseline
Control —10 7b —20 6" —71 7b
P <0.005 NS <0.005
DM 8±12 —9±5 18± 7
Lysozymuria, pUg/day
Control 0 56 20 1023 484
P <0.01c <0.Olc
DM 0 0 0
Renal cortical gentamicin, p.g/g wet tissue
Control 523 55 <0.1 708 77 <P0,1 513 28
P <0.005 <0.005 <0.001
DM 164 18 <0.005 280 21 NS 274 40d
2
3
2
C)
C)
-:z=t
I I I I I I
a N = 6 in each group. At baseline, control rats weighed 250 to 300g
and DM rats 200 to 250g. Baseline Ccr in mI/mm in these groups were:
control, day 3 group, 1.7 0.1, day 6 group, 2.5 0.1, and day 9 group,
2.2 0.1; DM, day 3 group, 2.4 0.2, day 6 group, 2.6 0.03, and day
9 group, 2.6 0.2 mI/mm; P values C vs. DM <0.025, >0.05 and >0.05,
respectively. Urine volume ranged from 14 to 18 mI/day in controls and
from 100 to 160 mI/day in DM rats. Glycosuria ranged from 4 to 8 mgI
day in controls and from 8 to 13 glday in DM animals.
"P < 0.001 from baseline.
Mann-Whitney U test {24].
d P < 0.05 day 3 vs. day 9.
although it was of borderline significance in the DM-H rats
(single-tailed Student's t test; P < 0.05). Baseline sodium
excretion (Table 2), fractional sodium excretion (FENa) and
osmolal clearance (Csm) (Table 1) were also significantly
higher in the DM and DM-H animals than in controls.
Table 2 summarizes selected balance data at baseline for all
groups. Because there were no statistically significant differ-
ences, the data for the DM and DM-H animals were pooled for
simplicity of presentation. Water and food intake were six- and
three-fold higher, respectively (P < 0.001), in the DM rats.
Likewise, sodium and potassium intake were significantly high-
er (P < 0.001) compared to control animals.
Diabetes insipidus rats. The DI animals had lower body
weights and plasma creatinine concentrations, but their plasma
sodium levels were higher when compared to the Brattleboro
controls (Table 1). As expected urine volume was higher (P <
0.001), urine osmolality (P < 0.001) and Cr (P < 0.025) were
lower and water intake was eight-fold greater in the DI rats (P <
0.001). There were no differences noted in food, sodium, or
potassium intake or urinary excretion of sodium, potassium,
glucose, or total solute between the DI and BC groups. As
expected, baseline C0sm was lower (P < 0.001) in the BC and
DI rats than in the DM or DM-H groups. Of note, however, in
the BC and DI animals baseline FENa were not significantly
different from the values observed in the rats with diabetes
mellitus.
SHAM control and DM rats. Table 3 shows selected data
obtained at baseline and during days 4, 7, 11, and 14 of the study
of Sprague-Dawley SHAM control and DM animals. Through-
out the experiment SHAM animals maintained stable body
weight, plasma glucose, urine volume, sodium, and glucose
excretion and Ce,-. In the SHAM DM animals there was a slight
increase in hematocrit.
0
Controls
Diabetes mellitus-high dose
5000 — Diabetes mellitus
— — Brattleboro controls
Diabetes insipidus
— (X±SEM)
1000 —
:: I.,
Days 1 2 3 4 5 6 7 8 9 10 11 12 13 14J
Gentamicin, 40mg/kg BW/day
Fig. 1. Sequential changes in plasma creatinine, creatinine clearance,
and lysozymuria in Sprague-Dawley and Brattleboro rats following the
administration of gentamicin. All groups received gentamicin at the
dose indicated in the figure, with the exception of the diabetes mellitus-
high dose group (asterisk), which received gentamicin sulfate at a dose
of 70 mg/kg BW per day for 14 days. For brevity, paired and unpaired P
values are described in the text.
Rena/function after gentamicin administration (Figs. / and 2)
Diabetes mellitus rats. Figure 1 illustrates the sequential
changes in renal function during gentamicin administration. The
Sprague-Dawley control group exhibited a progressive rise in
plasma creatinine concentration beginning on day 4 and reach-
ing an average of 5.5 2.0 mgldl by day 14 (P < 0.005). The
maximal increase from baseline was 6.3 1.9 mg/dl (P < 0.02),
and only one out of nine animals had a peak value lower than
1.5 mgldl. Two control animals died before day 11. The changes
in BUN paralleled those of plasma creatinine, with BUN
increasing from a baseline of 16 1 mgldl to a peak of 187 45
mgldl (P < 0.02).
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plasma creatinine and BUN concentrations were remarkably
constant throughout the experiment.
The DM rats exhibited a progressive modest increase in Cc.
from a baseline value of 2.3 0.2 mI/mm to 3.1 0.3 mi/mm on
day 11 (P < 0.001), while the CCr remained essentially un-
changed in the DM-H group. There were no differences in Car,
however, between the two DM groups at any time during the
experiments. It was not possible to detect lysozymuria in the
DM and DM-H rats at any time during gentamicin administra-
tion.
Figure 2 illustrates the marked differences in peak lysozy-
muria (top panel) and maximal change in Cc (middle panel)
between Sprague-Dawley control and DM and DM-H groups.
The control rats showed an increase in urine volume from a
baseline of 11 1 mI/day to a maximal value of 16 2 mI/day (P
< 0.02). Urine osmolality decreased from an initial value of
1316 108 mOsm/kg water to 639 185 mOsm/kg water on day
14 (P < 0.025). Most of the decline was already present by day
7, 706 177 mOsm/kg water, P < 0.025.
The DM rats exhibited a progressive and statistically signifi-
cant increase in urine volume reaching its peak by day 11(177
13 mllday, P < 0.005). On the other hand, urine flow did not
change significantly in the DM-H group. Urine osmolality
showed a modest progressive decrease in the DM animals from
960 23 mOsm/kg water at baseline to 845 24 mOsm/kg
water on day 11 (P < 0.005), while it remained essentially
unchanged in the DM-H rats.
Glucosuria increased significantly and in a progressive fash-
ion in the DM group following gentamicin, reaching a peak of
15.5 1.5 g/day by day 11 (P <0.001), and thereafter showed a
Diabetes DM-high Brattleboro Diabetes tendency to decline (13.4 1.0 glday on day 14). Urinary
mellitus dose control insipidus glucose excretion also increased in the DM-H group, reaching
its highest value on day 4 (12.7 1.1 g/day; P < 0.025),
thereafter progressively declining to its baseline value (10.5
1.1 g/day on day 14). Except on day 11 (P < 0.025), there were
no differences in glycosuria between the DM and DM-H ani-
mals. From a baseline level of 8 1 mg/day, the Sprague-
Dawley control rats also exhibited a progressive and significant,
albeit very small, increase in urinary glucose excretion to a
peak value of 127 65 mg/day (P < 0.05).
While plasma glucose concentrations remained unchanged in
the DM rats, a modest increase was observed in the DM-H
animals, peaking at 702 43 mg/dl on day 11 from a baseline
value of 606 29 mg/dl (P < 0.025).
Diabetes insipidus rats (Figs. 1 and 2). The Brattleboro
control rats exhibited a small, but progressive increase in
plasma creatinine concentration following gentamicin (Fig. 1).
By day 7 plasma creatinine had risen to 0.6 0.02 mg/dl from a
baseline of 0.5 0.01 mg/dl(P <0.05) and to a maximum of 1.4
0.4 mg/dl on day 14 (P <0.05). The highest BUN concentra-
tion was observed on day 11(53 11 mg/dl, P < 0.02) from a
baseline value of 20 1 mg/dl. All animals survived the 2
experimental weeks.
The Ccr decreased progressively in the BC rats reaching a
value of 0.7 0.1 ml/min on day 11 (P <0.001) from a baseline
1.6 0.1 mI/mm; P < 0.02. From undetectable baseline levels
lysozymuria increased progressively in the BC animals, reach-
ing its peak on day 11 (P < 0.01). In these rats lysozymuria was
evident on day 4 (43 15 j.g/day, P < 0.05).
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Fig. 2. Peak lysozymuria, maximal change in creatinine clearance, and
kidney gentamicin content in Sprague-Dawley and Brattleboro rats
following gentamicin administration. All groups, with the exception of
DM-H rats, were injected daily for 14 days with gentamicin sulfate at a
dose of 40 mg/kg BW. The DM-H rats received 70 mg/kg BW daily of
gentamicin for 14 days. The asterisk indicates that lysozymuria was
undetectable in the DM and DM-H groups. When gentamicin kidney
content (bottom panel) was calculated per gram of dry tissue the
following results were obtained: controls 2410 214 g/g dry kidney;
DM1319 141;DM-H 1666 190; BC 1817 314 and DI 1567 259.
P values: control vs. DM <0.001; control vs. DM-H <0.05; DM vs.
DM-H, and BC vs. DI nonsignificant. Other statistical differences not
illustrated are described in the text.
There was a statistically significant decrease in Cc,- by day 4
(P < 0.05) in the control group. This decline in GFR steadily
progressed until day 11, when Cc,- reached a value of 0.4 0.2
mI/mm (P < 0.005) from a baseline of 1.6 0.2 mI/mm.
Thereafter, there was no further decline.
The pattern of urinary lysozyme excretion, a marker of
proximal tubular damage, is depicted at the bottom of Figure 1.
From undetectable baseline levels, lysozymuria significantly
increased in the control animals reaching its peak on day 11 (P
< 0.001). It should be noted that lysozymuria was already
present in these animals by day 4 (27 7 i.g/day; P <0.01).
In marked contrast to the findings in the Sprague-Dawley
control rats, the two DM groups showed no evidence of
decreased renal function or appearance of lysozymuria through-
out the experimental period and all animals survived. The
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Table 5. Light microscopy assessment of the degree of tubular necrosis after gentamicin administrations
Groups No. animals
Dose of
gentamicin
mg/kg/day/14 days
Tubular necrosis scoreb
Mean Range
Sprague-Dawley rats
C 8 40 3.81 0.13 3 to 4
DM 9 40 0 0
DM-H 6 70 0.42 0.08 0 to 0.5
SHAM-C 5 — 0 0
SHAM-DM 5 — 0 0
Brattleboro rats
BC 9 40 3.11 0.26 2 to 4
DI 8 40 2.00 0.34 0.5 to 3
Statistical comparison
Groups P vlaue Groups P value
C vs. DM <0.01 BC vs. DI NS
C vs. DM-H <0.01 C vs. BC <0.05
DM vs. DM-H NS C vs. DL <0.05
DM-H vs. SHAM-DM NS DM vs. DI <0.01
DM-H vs. SHAM-C NS DM-H vs. DI <0.01
DM-H vs. BC <0.01
Animals were sacrificed on day 15 of the study.
b Tubular necrosis score: 0, no cell necrosis; 1, mild, usually single cell necrosis in sparse tubules; 2, moderate, sparse tubules show more than
one cell involved; 3, marked, tubules in almost every high power field exhibiting total necrosis; 4, massive, total necrosis.
Mann-Whitney U test was used to complete the data [24].
Abbreviations are the same as in Tables 1 and 3 in addition to SHAM-C, C rats injected with Ringer's solution and SHAM-D, D rats injected with
Ringer's solution.
In the DI group, plasma creatinine rose less than in the BC
group, from a baseline value of 0.4 0.02 mg/dl to a maximum
of 0.6 0.08 mg/dl on day 14 (Fig. 1). The latter value was
significantly greater (F < 0.01) than baseline, as was the value
on day 11 (P < 0.005). BUN concentrations exhibited a similar
pattern (baseline 18 2 mgldl, day 11 30 3 mg/dl, P <0.005).
All animals were alive at the end of the experiment. The Cr in
the DI group declined to a lesser degree than in the BC animals
(Figs. 1 and 2). The maximal decrease in CCr occurred on day 11
(baseline 1.3 0.1 mg/day to 0.9 0.1 mI/day, P < 0.005),
however, no significant changes were observed at days 4 or 7.
Likewise, lysozymuria, not present at baseline, was only de-
tected in one of nine DI animals at day 4, while it was
significantly greater than baseline at day 7 (263 91 g!day, P
<0.05), day 11(1609 343 g/day, P < 0.01) and day 14 (1663
733 g/day, P < 0.01).
In Figure 2 it can be appreciated that peak lysozymuria was
not statistically different between BC (4705 1486 j.g/day) and
DI (2349 691 pg/day) (P < 0.2). Likewise, although the
maximal percent decrease in CCr was 56 7 in the BC rats, this
value was not statistically different from the decrease observed
in the DI animals (38 8%, P < 0.1).
While the BC rats maintained constant urine volumes
throughout the experiment, a striking decline in urine osmolali-
ty was observed. This decrease was apparent by day 7 (baseline
956 56 mOsm/kg water, day 7 683 26 mOsmlkg water, P <
0.001) and continued until reaching its maximum on day 14 (521
37 mOsm/kg water; P < 0.001). In contrast, the DI animals
exhibited a marked decrease in urine flow while receiving
gentamicin. Urine volume decreased from a mean baseline of
192 17 ml/day to 114 11/day on day 11 (P < 0.005).
Thereafter, urine flow increased slightly. Concomitant with
this, urine osmolality increased from a baseline of 124 7
mOsm/kg water to a peak value of 199 26 mOsm/kg water on
day 11 (P < 0.025). Urinary glucose excretion increased in the
BC rats from a baseline value of 3 0.4 mg/day to a peak value
of 67 20 mg/day (P < 0.025). Similarly, glycosuria reached a
peak of 51 3 mg/day in the DI animals (P < 0.005).
Differences in urinary glucose excretion were not detected
between the two groups.
Plasma potassium, hematocrit, and body weight. Unlike the
dog treated with high dose gentamicin [251, a decline in serum
potassium levels was not observed in any of the groups.
By the end of the experiments the hematocrit decreased
significantly in all groups. The decrease, however, was greater
in the animals that developed renal failure (Final hematocrit: C
40.5 2.1%P<0.005;BC41.3 0.7%P<0.001;D140.9
0.7% P < 0.001) than in the protected rats (DM 45.2 0.9% P <
0.01; DM-H 45.8 0.8% P < 0.01). This difference may have
resulted from the effect of renal failure.
The Sprague-Dawley control rats exhibited a marked loss of
body weight (20.9%, P < 0.005) after 2 weeks of gentamicin
administration, while the weight loss was less in the BC (9.5%,
P < 0.01) and DI animals (5.3%, P < 0.02). On the other hand,
the DM rats gained weight (DM 2.7% P < 0.05; DM-H 3.7% P
<0.01).
Gentamicin renal tissue content. Figure 2 illustrates (bottom
panel) the kidney tissue content of gentamicin expressed in g/g
wet kidney tissue for all the groups as measured on day 15 of the
experiment. The highest kidney gentamicin content was present
in the Sprague-Dawley control rats. The DM-H rats did not
differ in their kidney content of gentamicin from the DM
animals despite receiving almost twice the daily dose of genta-
micin. Although kidney gentamicin content in the DM-H rats
was not significantly different from the Sprague-Dawley con-
trols when expressed per wet kidney tissue weight, this value
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Fig. 3. Light microscopy findings of a Sprague-Dawley control (A) and a streptozotocin-induced diabetes me/titus (B) rat injected with gentamicin,
40mg/kg B Wlday for 14 days. A Extensive necrosis of proximal tubular cells with numerous cellular debris in tubular. B Preservation of tubular ar-
chitecture, including brushborder membranes of proximal tubules is seen. Glycogen deposits are observed in pars recta of proximal tubules.
Glomeruli appear normal. Magnification, x420.
became significantly lower (P < 0.05) when calculated per dry
kidney weight (Fig. 2, legend). No differences in gentamicin
content were observed between BC and DI rats. The lower
kidney gentamicin values found in the DM animals could not be
attributed to a higher percent of kidney water content: DM 81
0.8; DM-H 82 0.4; controls 83 0.4; BC 83 0.7 and DI 83
0.8. P values, DM vs. DM-H and BC vs. DI, were not
significant; DM vs. controls <0.02; DM-H vs. controls <0.05.
The renal cortical gentamicin content after 3, 6, and 9 days of
gentamicin administration is summarized on Table 5. It can be
easily appreciated that as early as day 3 after commencing
gentamicin the DM rats had a cortical gentamicin content that
was three times lower than that of the control rats. This
difference persisted throughout our study. The peak value of
renal cortical gentamicin on the control rats was achieved on
day 6 and thereafter the content decreased. Of importance in
these animals by day 3 there was no lysozymuria detected and
changes in CCr were minimal. By day 6, however, mild lysozy-.
muria appeared in all the control rats and Ccr had decreased by
20% (P < 0.001). A marked decrease in Ccr and more severe
lysozymuria was evident on day 9 of the study. As in the other
DM groups studied, Ccr did not decrease and lysozymuria was
undetectable throughout the experiment in the DM animals.
Morphologic findings (Figs. 3 and 4). Morphologic abnormal-
ities were limited to the proximal tubules. The degree of tubular
necrosis is presented in a quantitative fashion on Table 5.
Diabetes mellitus rats: By light microscopy kidneys from
Sprague-Dawley control rats exhibited severe proximal tubular
damage with extensive necrosis of tubular cells and occlusion of
tubular lumen by cellular debris (Fig. 3A). In contrast, kidneys
obtained from DM and DM-H groups showed integrity of
tubular structures, with preservation of brushborder, open
lumina, and absence of debris (Fig. 3B). The control animals
exhibited the highest tubular necrosis score, 3.81 0.13, while
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Fig. 4. Electron micrographs of proximal tubular cells of a Sprague-Dawley control rat (A) and a streptozotocin-induced diabetes mellitus (B) rat
injected with gentamicin, 40 mg/kg BW/day for 14 days. A Cell architecture of the control rat is totally disorganized with presence of myeloid
bodies, vacuoles, and degeneration of organelles. B Architecture of cells of the diabetes mellitus rat is preserved. Note the normal brushborder
membranes (bb) and the presence of myeloid bodies within lysosomes (arrows). Magnification, x 12,000.
the DM (0 score) and DM-H rats (0.42 0.08) scores did not
differ between each other or from that of SHAM DM or SHAM
control groups (Table 5). Glycogen deposits were seen in the
pars recta of the proximal tubule of DM animals (Fig. 3B).
Glomerular mesangial changes were not observed in the DM
rats [26, 27]. Electron microscopic evaluation of renal tissue
obtained from Sprague-Dawley control rats revealed marked
cellular abnormalities, ranging from swollen mitochondria and
rough endoplasmic reticulum, cytoplasmic vacuoles and lipid
droplets to hydropic appearance of the cytoplasma and progres-
sive disappearance of organelles (Fig. 4A). There was preserva-
tion of the cellular structures in the kidneys obtained from DM
(Fig. 4B) and DM-H rats. Myeloid bodies were present in
control, DM, and DM-H kidneys (Fig. 4). Diabetes insipidus
rats: Brattleboro control and DI animals exhibited findings by
light and electron microscopy similar to those described for
Sprague-Dawley controls. Tubular abnormalities, however, pre-
sented a focal distribution in the DI rats and were less marked
than in Sprague-Dawley controls (P < 0.05). Despite elevated
urine flow rates in the DI rats their tubular necrosis score was
significantly different than that of DM and DM-H rats (P < 0.01)
(Table 5). SHAM rats:Kidneys from SHAM control and SHAM
DM rats did not reveal any morphologic abnormalities.
Discussion
We observed a striking difference in the development of
gentamicin-induced nephrotoxicity between Sprague-Dawley
control and diabetes mellitus rats receiving the same dosage of
the aminoglycoside. While the control animals developed acute
renal failure, severe lysozymuria, glycosuria, and tubular ne-
crosis, complete protection was afforded to the rats with
streptozotocin-induced diabetes mellitus (Fig. 1 to 4; Table 5).
In the control rats appearance of lysozymuria, decrease in
Ccr and urine osmolality were detected as early as day 4 after
gentamicin administration, with the maximal changes occurring
by day 11. Thereafter, some animals showed a tendency to
recover. As judged by the maximal decrease in Ccr, six out of
nine control rats exhibited severe renal failure (82 to 100%
decrease); only one animal had a moderate decrease (48%) (Fig.
5). Although the degree of renal failure in the control rats was
more severe than reported previously [12, 28, 29], the pattern of
functional change was not different from that described in
similarly treated animals [12, 28, 29]. Because Sprague-Dawley
SHAM control animals maintained normal renal function
throughout the studies (Table 3), the severity of the renal failure
observed in the Sprague-Dawley control rats cannot be attribut-
ed to the experimental protocol itself.
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In marked contrast, the DM rats receiving the same gentami-
cm dose exhibited preservation of renal function and structure
(Figs. 1 to 4; Table 5). It is noteworthy, that when diabetic
animals were treated with a higher dose of gentamicin (DM-H
group), they were also able to maintain normal renal function
and structure. Of importance lysozymuria was undetectable in
the DM and DM-H groups, further suggesting that gentamicin-
induced early proximal tubular damage was not present in these
animals [30, 31].
We do not have a satisfactory explanation for the progressive
increase in CCr observed in the DM rats. In these animals water,
food, and salt intake remained at baseline levels throughout the
experimental period, and the changes in hematocrit were simi-
lar to those shown by the DM-H group. The glycosuria ob-
served after gentamicin in the control rats paralleled renal
impairment as described in rabbits [321 and dogs [251. The cause
of the increased glucose excretion observed in the DM and DM-
H rats, however, cannot be explained by the present studies.
In interpreting kidney tissue gentamicin concentrations the
following considerations are pertinent. First, values measured
on day 15 in the unprotected control rats probably represented
underestimation of the peak tissue levels because gentamicin
levels decrease with the development of renal failure [12, 29].
This has been attributed either to an impaired gentamicin
uptake secondary to a decreased GFR [33] or to a loss of
gentamicin-ladden proximal tubular cells due to acute tubular
necrosis [28, 29]. Indeed, when renal cortical gentamicin con-
tent was measured after 3 and 6 days of aminoglycoside
therapy, significant lower levels were found in the DM rats
(Table 4). In these animals peak levels also occurred by day 6 as
described previously for nondiabetic rats [12, 29].
Although DM-H animals received a dose of gentamicin that
was 75% greater than that given to the DM rats, gentamicin
content in the former group was only 28% higher (1666 190
p.g/g dry/weight kidney tissue) than in the DM animals (1319
14 pgIg dry kidney tissue, P > 0.05). These considerations
notwithstanding, it is evident that the protection against genta-
micin nephrotoxicity demonstrated in the DM animals was
associated with an early lower renal cortical accumulation of
gentamicin (Table 4).
The major difference observed between the Brattleboro and
Sprague-Dawley control rats was the severity of the renal
failure in the latter, as shown by the maximal decrease in CCr
(BC 56 7%; Sprague-Dawley controls 85 6% P < 0.01; Fig.
2). This may have been related to a different animal strain
susceptibility to gentamicin nephrotoxicity.
A modest impairment in renal function with a delayed appear-
ance of lysozymuria, mild glygcosuria, and focal tubular necro-
sis followed administration of gentamicin in the DI rats (Figs. 1
and 2). The decrease in urine flow and increase in urine
osmolality observed in the DI animals after gentamicin was
probably secondary to the decline in GFR and slowing of the
tubular fluid flow rate in the distal nephron [4, 34, 35]. Other
mechanisms, particularly when decreases in GFR are minimal
in rats with diabetes insipidus have also been suggested [36].
Despite an apparent milder degree of nephrotoxicity in the DI
animals gentamicin kidney content was not different between
DI and BC groups (Fig. 2). Thus, it appears that the DI rats
exhibited partial protection from gentamicin-induced nephro-
toxicity. This finding differs from that reported in glycerol-
treated DI rats, where protection from acute renal failure was
not observed [4, 37].
A number of mechanisms should be discussed in relation to
the protection against gentamicin nephrotoxicity exhibited by
the DM rats. Some of these might decrease gentamicin uptake
by the kidney and therefore result in protection, others might
involve independent protective mechanism(s). The role of
GFR, urine flow, and solute excretion rates will be examined
first.
Rats with hyperglycemia of a relatively short duration (not
exceeding 9 months) have enhanced GFR, kidney weight, and
glomerular volume [27, 38]. In this study the DM and DM-H
rats had a Cr that on the average was 44% higher than in the
control animals. Similarly, kidney weights were greater in the
DM (1.78 0.05 g, one kidney) and DM-H animals (1.80 0.11
g) than in control rats (1.48 0.13 g; P < 0.05).
Because gentamicin uptake by the proximal tubule appears to
be load dependent (absolute absorption increasing with en-
hanced tubular gentamicin load) [39], it is conceivable that
animals with a higher GFR may accumulate more of the
aminoglycoside because of a higher filtered load enhancing the
possibility of toxicity. On the other hand, it is also possible that
with continuous drug administration a lower fraction of the
filtered load might be reabsorbed [39]. We elected to approach
the problem of higher GFR in the diabetic animals by giving a
higher dose of gentamicin in an effort to increase the filtered
load of the drug. Despite this maneuver, the kidney of diabetic
animals accumulated gentamicin to approximately the same
extent in the DM-H and DM groups.
Occasionally, control rats have a baseline CCrnot lower than
that of the DM rats and after gentamicin they develop acute
renal failure of a magnitude similar to that of the control animals
reported here. This is exemplified by the animals sacrificed on
day 9 presented in Table 4: Ccr (mi/mm), controls (N = 6)
baseline2.2±0.1;day3,l.5±0.l;day6,l.7±O.l;andday9,
0.6 0.1. DM (N = 6) baseline 2.6 0.2 (NS); day 3, 2.3 0.2
(P <0.005); day 6,2.7 0.2 (P <0.001); and day 9,3.1 0.4(P
<0.001). Thus, even when baseline CCr was not different, the
control rats were not protected from gentamicin. Therefore, it
appears that within the limits of this experiment GFR was not a
major determinant of protection.
Although acute hydration did not result in a lower cortical
gentamicin concentration in dogs [11] or diminished nephrotoxi-
city in rats [15], chronic high-rate water diuresis in the DI rats
was associated with partial protection from gentamicin-nephro-
toxicity (Fig. 1). It may be argued that the rat with hereditary DI
is not an adequate model to study the protective effect of high
urine flow rate against a drug which is predominantly reab-
sorbed by the proximal tubule. In these animals proximal
tubular filtrate reabsorption and tubule fluid flow rate are
normal [40] and might be expected to be increased or de-
creased, respectively, if the rats are dehydrated. The DI
animals are usually chronically dehydrated [41], as it was
suggested in the present study by their elevated serum sodium,
osmolality and lower GFR (Table 1). It is of interest to note
that, contrary to what might have been expected, the DI rats did
not have a higher gentamicin content than the BC animals,
suggesting that the partial protection might have been related in
part to the high water diuresis. In the DI animals tubules
characteristically were open and dilated and no tubular casts or
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debris were observed as seen in the BC and notably in the
Sprague-Dawley control rats (Fig. 3A). Under these conditions,
the effect of tubular obstruction on renal function may have
been minimized in the DI rats [4].
Examination of Figure 5 illustrates that a clear separation of
the animals exhibiting complete protection from gentamicin
toxicity (DM and DM-H groups) from those with partial (DI) or
no protection (S-D and BC controls) is obtained when the
maximal change in Ccr following gentamicin is plotted versus
baseline osmolal clearance. The figure also shows that baseline
urine flow rate alone cannot explain the protection observed in
the DM and DM-H rats because the animals with the highest
baseline urine flow rates (DI rats) exhibited moderate but
variable degrees of renal impairment after the aminoglycoside.
The magnitude of the protective natnuresis observed in long-
term saline drinking animals in various nephrotoxic models,
such as glycerol, uranyl-nitrate, and mercuric chloride is in the
order of 3 to 6 mEq/day/lOOg BW [5, 9, 10]. This contrasts with
the sodium excretion in the DM rats in our study, which was on
the average two to four times lower; 1.4 mEq/day/lOOg BW.
Sprague-Dawley control rats, on the other hand, had an average
sodium excretion of 0.34 mEq/day/lOOg BW, a value similar to
that reported in animals drinking 10% glucose which were not
protected from ARF after glycerol administration [5].
Although most control Sprague-Dawley rats had a lower
baseline FENa than DM animals, it should be noted that one
group of control rats studied (Table 4, day 9 group), was not
protected from the nephrotoxic effects of gentamicin despite
having a baseline sodium excretion rate that was not different
from that of DM animals. Furthermore, BC rats, with similar
baseline FENa to that of DM and DM-H animals, also were not
protected from gentamicin. No functional or morphologic pro-
tection was reported in the Fischer 344 rat when chronic 1%
sodium chloride [12] or bicarbonate [17] water drinking pre-
ceeded gentamicin administration. On the other hand, long-
term high salt intake partially blunted the decrease in glomeru-
lar function caused by 10 days of gentamicin administration
without evidence of morphologic protection [19]. Sodium ex-
cretion rates were not provided in these studies [12, 17, 19].
Because glucose and sodium chloride are the principal sol-
utes excreted by the DM rats, a correlation (Spearman's rank)
was undertaken between the maximal change in Ccr after
gentamicin and baseline urine flow, sodium and glucose excre-
tion rates, and osmolal clearance considering all groups togeth-
er. The best correlation was given by baseline osmolal clear-
ance(r 0.82, P <0.001), followed by sodium excretion (rO.76, P
<0.001), glucose excretion (r 0.66, P < 0.001), and urine flow
rate (r 0.45, P < 0.005). Taken as a whole, these data might
suggest that the enhanced solute excretion was responsible for
the protection of the diabetic animals. It should be pointed out,
however, that close examination of the Cosm data of diabetic
animals (Fig. 5, upper part right panel) reveals that no positive
correlation exists between the maximal change in Cr and
baseline Cosm in the individual DM and DM-H groups. Because
of this, the protection observed in the diabetic animals from
gentamicin, although appearing associated to the higher osmolal
clearance, cannot be attributed to it.
In addition to enhanced solute excretion in DM animals,
consideration should be given also to other aspects of the
diabetic state which might be involved in the mechanism(s) of
protection.
In the rat with experimental diabetes hyperglycemia pro-
duces extracellular hyperosmolality with subsequent extracel-
lular volume expansion and suppression of renin release [42,
43]. Although we have not measured extracellular fluid volume
or renin-angiotensin levels in our DM rats, there is no evidence
to assume that these animals were different from those reported
previously [42, 43].
Although attenuation of the severity of experimental ARF
has been recently shown to be independent of the activity of the
renin-angiotensin system [10, 44], it is conceivable that the
altered renin-angiotensin state in experimental diabetes [42, 43]
might have influenced protection against gentamicin nephrotox-
icity. Indeed, Shor et al [19] have recently suggested that the
gentamicin-induced reduction in glomerular ultrafiltration was
mediated by renin-angiotensin activation. Of importance, they
noted that whereas captopril and high salt intake were both
effective in affording functional protection against gentamicin,
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Fig. 5. Plot of the maximal change in creatinine
clearance versus baseline urine flow or osmolal
clearance in Sprague-Dawley and Brattleboro
rats following genlamicin administration. The
following symbols identify the animal groups:
Sprague-Dawley controls (•); diabetes mellitus
(0); diabetes mellitus-high dose (U); Brattle-
boro controls (is) and diabetes insipidus (A).
Gentamicin dosage as in Figure 1.
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neither substance ameliorated the striking morphologic changes
in the proximal tubule epithelia [19]. This finding suggests that
events occurring early in gentamicin nephrotoxicity in proximal
tubular cells precede the activation of the renin-angiotensin
system, which, in turn, mediates the decrease in GFR. Because
the functional protection observed in the DM rats was associat-
ed with normal morphology, it may be concluded that the
blunting of the renin-angiotensin system in the DM rats was not
the only mechanism involved in the protection. Furthermore, it
also suggests that the protective mechanism(s) in the DM rats
operated at the proximal tubule level.
It is currently accepted that the accumulation of gentamicin
in the renal cortex is perhaps the major determinant of its
nephrotoxic effect. The accumulation of the drug within the
lysosomes induces an extensive cellular dysfunction which, by
inhibition of lysosomal enzymes involved in the metabolism of
polar lipids or by altering lysosomal membrane permeability,
may subsequently lead to cell necrosis [1, 33, 45]. In our study
the total protection observed in DM rats was associated with a
lower renal cortical gentamicin content, suggesting that factors
influencing the early cellular uptake of gentamicin may have
determined the protection exhibited by these animals.
First, the diabetes-induced osmotic diuresis may have de-
creased the tubular uptake of gentamicin. To our knowledge,
published data do not exist that report a protective effect of
solute diuresis of the magnitude obtained in our DM animals on
gentamicin uptake and nephrotoxicity [46].
Second, the possibility exists that the enhanced renal glucose
transport of diabetic rats [47] might somehow interfere with
gentamicin uptake by the proximal tubules. There are to our
best knowledge no available data on the pharmacokinetics of
gentamicin or specifically on the particulars of its tubular
transport in DM animals. The aminosugars, as a pharmacologic
group, are known to interfere with glucose transport presum-
ably by acting as competitive inhibitors [48]. Of interest is the
striking protection against kanamycin ototoxicity found recent-
ly by Garcia-Quiroga et al [49] in alloxan-treated rats. Accord-
ing to these authors, kanamycin caused ototoxicity by interfer-
ing with the glucose transport system of the hair cells of the
base of the cochlea; hyperglycemia had a protective effect. In
contrast to our findings with gentamicin, these investigators did
not report an amelioration of the kanamycin-induced renal
damage in their diabetic animals. Unfortunately, a description
of renal studies was not provided [49].
Third, because phospholipids have been suggested recently
as possible proximal tubule brush border membrane receptors
or binding sites for aminoglycosides [50, 51], and abnormalities
of phospholipid metabolism have been described in experimen-
tal diabetes [52, 53], it is conceivable that an alteration in renal
phospholipids in the diabetic rats might have influenced genta-
micin uptake and thus protection.
In summary, it can be concluded that the complete protection
from gentamicin nephrotoxicity observed in the animals with
diabetes mellitus was secondary to an early lesser accumulation
of gentamicin in the kidney. The mechanism(s) whereby this
occurred remain(s) to be elucidated but cannot solely be
attributed to enhanced solute excretion.
Finally, we would like to suggest that the untreated rat with
streptozotocin-induced diabetes mellitus is a suitable model for
the study of the induction and preventive mechanisms of
gentamicin as well as other nephrotoxic agents [54].
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